Urelumab Biosimilar - Research Grade

In stock
Only %1 left
SKU
ICH5015
Add to Compare
Rating:
100 % of 100
$300.00
CoA
Add to Wish List

Urelumab Biosimilar - Research Grade

Product Details:

ichorbio's urelumab biosimilar is for Research Use Only (RUO)

Size:

ichorbio's RUO urelumab biosimilar is available in the following sizes: 1mg, 5mg, 10mg, 20mg, 50mg, 100mg ichorbio regularly manufactures bulk multi-gram amounts of this biosimilar - please contact us for pricing.

Target:

4-1BB

Isotype:

IgG4 (S228P)-kappa

Other Names:

4-1BB ligand receptor, T-cell antigen 4-1BB, Tnfrsf9, Ila, Ly63, CD137

Host:

CHO

Species Reactivity:

Human

Specificity:

Detects human 4-1BB.

Purification Method:

This recombinant protein was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background:

RUO urelumab is a humanized agonistic monoclonal antibody targeting 4-1BB with potential immunostimulatory and antineoplastic activities. Urelumab specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. .

Concentration:

1.0 - 5.0 mg/ml

Formulation:

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity:

>95% by SDS-PAGE and HPLC

Endotoxin:

≤ 1.0 EU/mg as determined by the LAL method

Storage:

Urelumab Biosimilar - Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Applications:

Functional Assays

Application Notes:

Each investigator should determine their own optimal working dilution for specific applications.

Use: ichorbio's urelumab biosimilar is for research use only (RUO). Isotype Control: Bulk Human IgG4 Isotype Control S228P (IB4) [ICH2257S228P]
More Information
Concentration 13.87mg/ml
isotype IgG4 (S228P)-kappa
Host CHO
Write Your Own Review
You're reviewing:Urelumab Biosimilar - Research Grade
Your Rating
Back to Top